US Physical Therapy - USPH Enterprise Value to EBITDA Ratio
U.S. Physical Therapy (USPH) revenues depend on Medicare policies and physician partnerships. The current EV/EBITDA valuation level helps identify the undervaluation of capital-intensive assets, while 20.63 shows the current volume of this metric. Stable demand for rehabilitation driven by an aging population ensures a predictable client inflow. Revenue is based on the management of a physical therapy center network and industrial healthcare.
Analytical breakdowns for U.S. Physical Therapy
- market price and analyst price targets:
- issuer market value details:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity U.S. Physical Therapy|USPH - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio U.S. Physical Therapy, Inc.|USPH - Company Total Debt Obligations|Debt to Book Value USPH|USPH - Company Long-Term Loans and Borrowings|Company Short-Term Debt U.S. Physical Therapy|Quick Ratio usph.com
- net income and valuation multiples indicators:
USPH - Final Profit|Future Profit U.S. Physical Therapy|USPH - Market Cap to Earnings|Future Price to Earnings U.S. Physical Therapy, Inc.|USPH - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple USPH|USPH - Operating income before deduction of amortization|Net earnings per share (EPS TTM) U.S. Physical Therapy|USPH - Net earnings per share for the last 12 months|Quarterly EPS earnings growth usph.com|USPH - Earnings growth in current year|Net earnings per share growth forecast for next year U.S. Physical Therapy
Comprehensive company analysis:US Physical Therapy Inc (USPH)
This ratio compares the total enterprise value, including net debt, to its operating profit before depreciation and amortization, allowing for an assessment of capital management efficiency under high debt loads. For U.S. Physical Therapy (USPH), which is currently in a phase of cyclical growth in demand for rehabilitation, the current EV/EBITDA multiple reflects the impact of reduced personnel costs on the company's overall investment attractiveness.
Key competitors
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization HCA Healthcare HCA|THC: Enterprise Value to Operating Income Before Depreciation|FMS: Enterprise Value to EBITDA Ratio|solventum.com - Enterprise Value to Operating Income Before Depreciation Ratio|EHC (Encompass Health Corporation) - Enterprise Value to EBITDA Ratio|Universal Health Services, Inc. (UHS) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio DVA|RadNet Management (RDNT) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Option Care Health (OPCH)|Total Company Value to Operating Income Before Depreciation Ratio surgerypartners.com|Premier - Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio National Vision Holdings, Inc. (EYE)|PGNY: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ARDT (Ardent Health Corp)|Select Medical (SEM) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio ASTH (astranahealth.com)|MD (Pediatrix) - EV/EBITDA Multiple|PNTG: Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio ORGO (Organogenesis Inc.)|NUTX - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Auna SA AUNA|Total Company Value to Operating Income Before Depreciation Ratio sbc-holdings.com (SBC)|Evolus - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio CHS CYH|SKIN: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio MediWound|BTMD (biote Corp.) - EV/EBITDA Multiple|EV/EBITDA Multiple thejoint.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization DocGo (DCGO)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PIII (p3hp.org)|Gain Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation EUDA|BMGL: Enterprise Value to EBITDA Ratio|CollPlant Biotechnologies - Enterprise Value to Operating Income Before Depreciation Ratio|CUPR: EV/EBITDA Multiple|Concord Medical Services Holdings - Business Value to Operating Income Before Depreciation|AMS (American Shared Hospital Services, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA MEDIROM Corp MRM|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Avalon GloboCare (ALBT)|DHAI (dih.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple XAGE (Carmell Therapeutics)|EV/EBITDA Multiple NewGenIvf Group NIVF|ATIP - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio CMAX|KDLY (Kindly MD, Inc.) - Enterprise Value to EBITDA Ratio|Company Value to EBITDA modivcare.com (MODV)|Enterprise Value to EBITDA Ratio NVOS|EV/EBITDA Multiple SunLink Health Systems, Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization IMAC Regeneration Centers (BACK)
